179 related articles for article (PubMed ID: 7497931)
1. [Can virus safety of blood products be assured?].
Krusius T
Duodecim; 1994; 110(13):1227-30. PubMed ID: 7497931
[No Abstract] [Full Text] [Related]
2. [Therapy with blood and blood products].
Kreienbühl G
Urologe A; 1996 Jan; 35(1):69-85. PubMed ID: 8851853
[No Abstract] [Full Text] [Related]
3. Beyond HIV, HBV and HCV--how to deal with other viruses?
Minor PD
Dev Biol (Basel); 2002; 108():15-9. PubMed ID: 12220138
[TBL] [Abstract][Full Text] [Related]
4. [Blood transfusion safety].
Koistinen J
Duodecim; 2004; 120(7):902-4. PubMed ID: 15154312
[No Abstract] [Full Text] [Related]
5. [Transfusion medicine--Scandinavian recommendations].
Jørgensen J; Jensson O; Eklund J; Kornstad L; Messeter L
Nord Med; 1994; 109(2):61-3. PubMed ID: 8121792
[TBL] [Abstract][Full Text] [Related]
6. Blood-borne viral infections.
Gürtler L
Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 3():S5-10; discussion S11-2. PubMed ID: 7749048
[TBL] [Abstract][Full Text] [Related]
7. [Blood - surely but safely!].
Offergeld R
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 Aug; 55(8):905-6. PubMed ID: 22842882
[No Abstract] [Full Text] [Related]
8. [Patient information and follow-up of transfusions: "a checked report"?].
Jullian H; Fuentes AM; Colavolpe JC; Gentille S
Ann Fr Anesth Reanim; 1999 Apr; 18(4):fi60-3. PubMed ID: 10365217
[No Abstract] [Full Text] [Related]
9. [Transfusion medicine in unified Europe].
Grigutsch V
Infusionsther Transfusionsmed; 1994 Nov; 21 Suppl 3():12-5. PubMed ID: 7841774
[TBL] [Abstract][Full Text] [Related]
10. [Safety of blood transfusions; need for 'hemo-vigilance'].
van Aken WG; van Rood JJ
Ned Tijdschr Geneeskd; 1998 Feb; 142(6):281-4. PubMed ID: 9562726
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of pathogens in blood and blood products.
Ben-Hur E
Med Health R I; 1998 Dec; 81(12):396-9. PubMed ID: 9884539
[No Abstract] [Full Text] [Related]
12. [Costs of safety of blood and blood products].
Seifried E; Soedel G
Zentralbl Chir; 1995; 120(8):584-92. PubMed ID: 7571889
[TBL] [Abstract][Full Text] [Related]
13. Pathogen inactivation of labile blood products.
Council of Europe Expert Committee in Blood Transfusion Study Group on Pathogen Inactivation of Labile Blood Components
Transfus Med; 2001 Jun; 11(3):149-75. PubMed ID: 11422945
[No Abstract] [Full Text] [Related]
14. What is safe blood?
Kapoor D; Sarin SK
J Assoc Physicians India; 2000 Mar; 48(3):335-42. PubMed ID: 11229123
[No Abstract] [Full Text] [Related]
15. [Infections as complications of blood transfusion]].
Kłos M
Przegl Epidemiol; 2001; 55 Suppl 3():4-9. PubMed ID: 11984956
[No Abstract] [Full Text] [Related]
16. [Quality assurance management system for therapy with blood and blood products].
Diekamp U
Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Oct; 33(10):664-5. PubMed ID: 9825053
[No Abstract] [Full Text] [Related]
17. [Virologic aspects of blood and plasma product safety].
Gärtner BC; Mueller-Lantzsch N
Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 Aug; 34(8):486-8. PubMed ID: 10494367
[No Abstract] [Full Text] [Related]
18. [XMRV is not pathogenic in human and has no significance for the safety of blood and blood products].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 Aug; 55(8):1057-60. PubMed ID: 22842897
[No Abstract] [Full Text] [Related]
19. Guidelines on the clinical use of leucocyte-depleted blood components. British Committee for Standards in Haematology, Blood Transfusion Task Force.
Transfus Med; 1998 Mar; 8(1):59-71. PubMed ID: 9569462
[No Abstract] [Full Text] [Related]
20. Status of NAT screening for HCV, HIV and HBV--experiences of the German Red Cross Blood Donation Services.
Seifried E; Findhammer S; Roth WK
Dev Biol (Basel); 2002; 108():23-7. PubMed ID: 12220139
[No Abstract] [Full Text] [Related]
[Next] [New Search]
